Consultations

The Faculty responds to a number of consultations throughout the year, principally from the UK Government and Department of Health, NICE, the GMC and UK and EU medicines regulatory bodies.

We would encourage individuals and organisations to bring consultations that they feel are relevant to the attention of the Faculty. Please contact Ben Cottam b.cottam@fpm.org.uk for more information.

Currently under review

Consultations currently under review by the Faculty are listed below. Faculty members are invited to submit any comments on these to Ben Cottam at b.cottam@fpm.org.uk.

There are currently no consultations for review.

Responses submitted by the Faculty

2012

• NICE Type 2 diabetes: Draft scope
• NICE Type 1 diabetes in adults: Draft scope
• MHRA consultation on recommendations made by the Commission on Human Medicines (CHM) on brand prescribing
• MHRA The revision of the European legislation on medical devices
• MHRA MLX376: Consultation on a proposal to introduce an early access to medicines scheme in the UK
• Health Select Committee Inquiry into the work of NICE
• MHRA MLX379: Transposition of Directive 2011/62/EU ("the Falsified Medicines Directive") into UK legislation
• MHRA MLX380: Consultation on the EC proposal for a clinical trials regulation
• Commons Science and Technology Select Committee Inquiry into Medical Implants
• EMA consultation on Good Pharmacovigilance Practice modules
• EMA consultation on Evaluation of Anticancer Medicinal Products in Man
• GMC consultation on recognising and approving trainers
• GMC Consultation on the licence to Practise and Revalidation Regulations 2012
• NRES consultation on the Health Research Authority
• MHRA MLX374 - Transposition of the EU pharmacovigilance directive
• GMC consultation on the routes to the GP and Specialist registers

2011

• Guideline on Pharmaceutical Development of Medicines for Paediatric use
• Employment-related settlement, Tier 5 and Overseas Domestic Workers (UK Border Agency)
• UK Influenza Preparedness Strategy (Department of Health)
• Concept paper on the revision of the Clinical Trials Directive 2001/20/EC (EC)
• Good Practice in Prescribing and Managing Medicines (GMC)
• Good Management Practice (GMC)
• National Postgraduate Professional Examinations (GMC)
• Developing the Healthcare Workforce (DH)
• Healthy People, Healthy Lives (DH)
• Value-based pricing (DH)

2010

• Cancer Drugs Fund (DH)
• Assessment of the Functioning of the Clinical Trials Directive (EC)
• Refection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted in third countries and submitted in MAAs to the EMA (EMA)
• Call for Evidence on the Revalidation of Doctors (Health Select Committee)
• Equity and Excellence: Liberating the NHS (DH)
• Liberating the NHS: Transparency in Outcomes (DH)
• Human Bodies in Medicine and Research (Nuffield Council)
• ABPI Code of Practice (PMCPA)